The active ingredient alpelizib targets a specific type of advanced breast cancer, not all advanced breast cancers as incorrectly stated in the 8 June report. The correct figure in the final paragraph is 350.

Ljubljana, 14 June - Alpelizib, the only targeted therapy for a specific type of advanced breast cancer, is now accessible to patients in Slovenia, making it one of the few countries where it is available. The Institute of Oncology already started treating patients in the compassionate use programme before the drug was registered.